Synergism and gene dose effect in HLA-DR serology.
By mixing HLA-DR antisera of different specificities and testing them against B lymphocytes carrying the corresponding antigens, a synergistic action of HLA-DR antibodies was revealed. Furthermore, it was demonstrated that HLA-DR and HLA-ABC antibodies may act synergistically against appropriate B cells. HLA-DR homozygous B lymphocytes were found to react more strongly with HLA-DR specific antisera than heterozygous cells, thus revealing a gene dose effect in HLA-DR serology. ABO antibodies were found not to react against B lymphocytes, either alone nor in concert with HLA-DR antisera. The practical implications of synergism and gene dose effect in HLA-DR serology are discussed.
D000017:ABO Blood-Group System / Q000276:immunology; D000818:Animals; D000961:Antilymphocyte Serum / Q000494:pharmacology*; D001402:B-Lymphocytes; D002469:Cell Separation; D003602:Cytotoxicity, Immunologic; D004303:Dosage Compensation, Genetic; D004357:Drug Synergism; D005260:Female; D006579:Heterozygote; D000949:Histocompatibility Antigens Class II; D006720:Homozygote; D006801:Humans; D011817:Rabbits; D013601:T-Lymphocytes
D000017:ABO Blood-Group System; D000961:Antilymphocyte Serum; D000949:Histocompatibility Antigens Class II